Kamila Z. W.
- Country
- Poland
- Department
- N/A
Research Overview
- Phase 3 Randomized Double-Blind Study of Orelabrutinib for Primary Progressive Multiple Sclerosis in Patients With PPMS
- Phase 3 Randomized Double‑Blind Study of Orelabrutinib vs Placebo on Disability Progression in Non‑Active Secondary Progressive Multiple Sclerosis
- Phase 3 Randomized, Double-Blind Study of Frexalimab (SAR441344) Versus Teriflunomide in Adults with Relapsing Multiple Sclerosis
Data & Insights
Has run more than one trial at 87 of 197 partner sites.
Specializations
Neurological Disorders
The investigator specializes in studying relapsing forms of multiple sclerosis, focusing on developing innovative therapeutic approaches for this chronic neurological condition.
- Multiple Sclerosis Management
- Autoimmune Neurological Disorders
- Relapsing MS Treatment Options
Their research extends to evaluating novel therapeutic agents for managing neurological autoimmune conditions.
Immunotherapy Research
The investigator focuses on studying immunomodulatory treatments and their applications in neurological conditions, particularly examining new therapeutic compounds.
- Novel Immunological Therapies
- Treatment Efficacy Assessment
- Therapeutic Response Monitoring
Their work involves evaluating the effectiveness of emerging treatments for autoimmune neurological disorders.
Clinical Outcomes
The investigator specializes in assessing therapeutic efficacy and safety profiles of treatments for neurological conditions, with particular attention to patient response metrics.
- Treatment Safety Evaluation
- Clinical Response Assessment
- Patient Outcome Measures
Their research encompasses comprehensive evaluation of treatment outcomes in neurological disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.